- Medical Malpractice
- Product
- Unsafe Drugs
- Pradaxa
- Metal-on-Metal Hip Implant Litigation
- Hip Implants - DePuy ASR Hip Recall
- Hip Implants - Zimmer Durom Cup Hip Recall
- Vaginal Mesh Litigation
- Vaginal Mesh - Bard Avaulta Surgical Mesh
- Accutane
- Actos
- Avandia
- Bisphosphonate Litigation
- Chantix
- Darvon and Darvocet Recall
- Knee Implant - Zimmer NexGen CR-Flex
- Kugel Hernia Mesh Patches
- Mentor ObTape Vaginal Sling
- Ortho Evra Birth Control Patch
- Yasmin, Yaz, and Ocella Birth Control
- Other/Archive Drug Products
- Personal Injuries
- Auto Accidents
- Nursing Home Abuse
Pfizer Agrees to Buy Wyeth for $68 Billion
Marking the largest pharmaceutical acquisition in nearly a decade, Pfizer, Inc., the world’s largest drug manufacturer announced today it will buy Wyeth for about $68 billion in a cash and stock acquisition valued at $50.19 per share. The deal happened as New York-based Pfizer is facing a host of issues including the expected loss of $13 billion a year in revenue for cholesterol fighter Lipitor starting in November 2011 when it gets generic competition, the payment of a hefty fine of $2.3 billion to settle allegations that it improperly marketed the now recalled anti-inflammatory drug Bextra, a low profit forecast for 2009, and nearly 8,000 job cuts starting immediately.
Click here to view 1/26/09 Pfizer Press Release